Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein SNAI2 (SNAI2, also known as SLUG) is a transcriptional repressor belonging to the Snail family of C2H2-type zinc finger transcription factors, encoded by the SNAI2 gene on human chromosome 8[1][6]. SNAI2 plays a crucial role in promoting epithelial to mesenchymal transition (EMT), a process essential for embryonic development, tissue repair, and tumor metastasis[1]. It binds to E-box DNA motifs to repress transcription of key adhesion molecules such as E-cadherin, facilitating cell migration and the acquisition of mesenchymal traits[1][6]. SNAI2 is critically important for neural crest cell development, influencing the differentiation and migration of these cells and contributing to the formation of various tissues including nerve and pigment cells (melanocytes)[2][3]. Mutations or deletions in SNAI2 are associated with disorders such as Waardenburg syndrome type II and piebaldism, both characterized by defects in pigmentation and, in Waardenburg syndrome, hearing loss[3]. In adults, SNAI2 functions in most tissues and maintains normal cellular function; dysregulated expression has been linked to cancer progression, particularly by promoting mesenchymal characteristics in carcinoma cells and enhancing metastatic potential[1][4]. **Note:** - No approved drugs are currently known to directly target SNAI2, and it primarily serves as a biomarker and a mechanistic node in EMT and oncogenesis[6]. - SNAI2 is a well-established transcription factor/therapeutic target by virtue of its roles in development and cancer, but it may present significant safety risks if targeted systemically due to broad developmental and homeostatic functions[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein SNAI2 (SNAI2).